Fig. 3: Binding antibody responses to core binding panel assessed by ELISA.

a Binding antibody responses to H5 A/Vietnam/1203/2004 assessed by ELISA. Geometric mean concentrations (ELISA Units per mL) and 95% confidence intervals are shown for all regimens and the quadrivalent seasonal influenza vaccinated comparator cohort (Q-SD FluVac). Placebo groups were pooled for analysis. The lower limit of quantification (LLOQ) for the assay is 55, the upper limit of quantification (ULOQ) for the assay is 107756, EU: ELISA Units. b Fold increase in H5 A/Vietnam/1203/2004 geometric mean concentrations with 95% CI at Day 29 from Day 1 baseline. Treatment groups are labeled 1-8. c Percentage of responders at Day 29 defined as those with a > 4-fold increase in H5 A/Vietnam/1203/2004 binding antibody response from Day 1 baseline or > 4-fold increase from LLOQ in case baseline ≤LLOQ. INFLUENZA G1 mHA treatment groups are labeled 1-8. d Binding antibody responses to the INFLUENZA G1 mHA-homologous antigen mHA H1 A/California/07/2009 assessed by ELISA. Geometric mean concentrations (ELISA Units per mL) and 95% confidence intervals are shown for all regimens and the quadrivalent seasonal influenza vaccinated comparator cohort (Q-SD FluVac). Placebo groups were pooled for analysis. LLOQ for the assay = 38, ULOQ for the assay = 648611, EU: ELISA Units. e Fold increase in mHA H1 A/California/07/2009 geometric mean concentrations with 95% CI at Day 29 from Day 1 baseline. f Percentage of responders at Day 29 defined as those with a > 4-fold increase in mHA H1 A/California/07/2009 binding antibody response from Day 1 baseline or > 4-fold increase from LLOQ in case baseline ≤LLOQ. INFLUENZA G1 mHA treatment groups are labeled 1–8. Sample sizes used for statistical analysis can be found in Supplementary Table 4. Source data are provided as a Source Data file.